Education and Training
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: SAR302503 (TG101348)
Eligibility
Inclusion Criteria:
- Completion of MF-TG101348-001 study
- Diagnosis of myelofibrosis
- At least 18 years of age
Exclusion Criteria:
- Any acute or chronic medical abnormality that may increase the risk associated with
study participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting